Parkinsons Disease-Pipeline Review, H2 2016

Parkinsons Disease-Pipeline Review, H2 2016


  • Products Id :- GMDHC8863IDB
  • |
  • Pages: 879
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H2 2016’, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

 

The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease

The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects

The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

 

Reasons to Buy

 

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Introduction 10

Parkinson's Disease Overview 11

Therapeutics Development 12

Parkinson's Disease - Therapeutics under Development by Companies 14

Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 30

Parkinson's Disease - Pipeline Products Glance 33

Parkinson's Disease - Products under Development by Companies 37

Parkinson's Disease - Products under Investigation by Universities/Institutes 56

Parkinson's Disease - Companies Involved in Therapeutics Development 60

Parkinson's Disease - Therapeutics Assessment 245

Drug Profiles 274

Parkinson's Disease - Dormant Projects 797

Parkinson's Disease - Discontinued Products 822

Parkinson's Disease - Product Development Milestones 825

Appendix 839

ist of Figures

Number of Products under Development for Parkinson's Disease, H2 2016 51

Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52

Number of Products under Development by Companies, H2 2016 53

Number of Products under Investigation by Universities/Institutes, H2 2016 69

Comparative Analysis by Late Stage Development, H2 2016 72

Comparative Analysis by Clinical Stage Development, H2 2016 73

Comparative Analysis by Early Stage Products, H2 2016 74

Comparative Analysis by Unknown Stage Development, H2 2016 75

Assessment by Monotherapy Products, H2 2016 284

Assessment by Combination Products, H2 2016 285

Number of Products by Top 10 Targets, H2 2016 286

Number of Products by Stage and Top 10 Targets, H2 2016 286

Number of Products by Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Top 10 Routes of Administration, H2 2016 309

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 309

Number of Products by Top 10 Molecule Types, H2 2016 311

Number of Products by Stage and Top 10 Molecule Types, H2 2016 311

List of Tables

Number of Products under Development for Parkinson's Disease, H2 2016 51

Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52

Number of Products under Development by Companies, H2 2016 53

Number of Products under Development by Companies, H2 2016 (Contd..1) 54

Number of Products under Development by Companies, H2 2016 (Contd..2) 55

Number of Products under Development by Companies, H2 2016 (Contd..3) 56

Number of Products under Development by Companies, H2 2016 (Contd..4) 57

Number of Products under Development by Companies, H2 2016 (Contd..5) 58

Number of Products under Development by Companies, H2 2016 (Contd..6) 59

Number of Products under Development by Companies, H2 2016 (Contd..7) 60

Number of Products under Development by Companies, H2 2016 (Contd..8) 61

Number of Products under Development by Companies, H2 2016 (Contd..9) 62

Number of Products under Development by Companies, H2 2016 (Contd..10) 63

Number of Products under Development by Companies, H2 2016 (Contd..11) 64

Number of Products under Development by Companies, H2 2016 (Contd..12) 65

Number of Products under Development by Companies, H2 2016 (Contd..13) 66

Number of Products under Development by Companies, H2 2016 (Contd..14) 67

Number of Products under Development by Companies, H2 2016 (Contd..15) 68

Number of Products under Investigation by Universities/Institutes, H2 2016 69

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 70

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 71

Comparative Analysis by Late Stage Development, H2 2016 72

Comparative Analysis by Clinical Stage Development, H2 2016 73

Comparative Analysis by Early Stage Development, H2 2016 74

Comparative Analysis by Unknown Stage Development, H2 2016 75

Products under Development by Companies, H2 2016 76

Products under Development by Companies, H2 2016 (Contd..1) 77

Products under Development by Companies, H2 2016 (Contd..2) 78

Products under Development by Companies, H2 2016 (Contd..3) 79

Products under Development by Companies, H2 2016 (Contd..4) 80

Products under Development by Companies, H2 2016 (Contd..5) 81

Products under Development by Companies, H2 2016 (Contd..6) 82

Products under Development by Companies, H2 2016 (Contd..7) 83

Products under Development by Companies, H2 2016 (Contd..8) 84

Products under Development by Companies, H2 2016 (Contd..9) 85

Products under Development by Companies, H2 2016 (Contd..10) 86

Products under Development by Companies, H2 2016 (Contd..11) 87

Products under Development by Companies, H2 2016 (Contd..12) 88

Products under Development by Companies, H2 2016 (Contd..13) 89

Products under Development by Companies, H2 2016 (Contd..14) 90

Products under Development by Companies, H2 2016 (Contd..15) 91

Products under Development by Companies, H2 2016 (Contd..16) 92

Products under Development by Companies, H2 2016 (Contd..17) 93

Products under Development by Companies, H2 2016 (Contd..18) 94

Products under Investigation by Universities/Institutes, H2 2016 95

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98

Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H2 2016 99

Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H2 2016 100

Parkinson's Disease - Pipeline by AbbVie Inc, H2 2016 101

Parkinson's Disease - Pipeline by AC Immune SA, H2 2016 102

Parkinson's Disease - Pipeline by Acelot Inc, H2 2016 103

Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H2 2016 104

Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 105

Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 106

Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 107

Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 108

Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2016 109

Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2016 110

Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 111

Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H2 2016 112

Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H2 2016 113

Parkinson's Disease - Pipeline by Angita BV, H2 2016 114

Parkinson's Disease - Pipeline by Antoxis Ltd, H2 2016 115

Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 116

Parkinson's Disease - Pipeline by APeT Holding BV, H2 2016 117

Parkinson's Disease - Pipeline by ApoPharma Inc, H2 2016 118

Parkinson's Disease - Pipeline by Aposense Ltd, H2 2016 119

Parkinson's Disease - Pipeline by Araclon Biotech SL, H2 2016 120

Parkinson's Disease - Pipeline by ArmaGen Inc, H2 2016 121

Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 122

Parkinson's Disease - Pipeline by AstraZeneca Plc, H2 2016 123

Parkinson's Disease - Pipeline by AudioCure Pharma GmbH, H2 2016 124

Parkinson's Disease - Pipeline by Berg LLC, H2 2016 125

Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H2 2016 126

Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H2 2016 127

Parkinson's Disease - Pipeline by BioArtic AB, H2 2016 128

Parkinson's Disease - Pipeline by Biogen Inc, H2 2016 129

Parkinson's Disease - Pipeline by BioHealthonomics Inc, H2 2016 130

Parkinson's Disease - Pipeline by Biopharm GmbH, H2 2016 131

Parkinson's Disease - Pipeline by Biotie Therapies Corp, H2 2016 132

Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 133

Parkinson's Disease - Pipeline by Calico LLC, H2 2016 134

Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2016 135

Parkinson's Disease - Pipeline by Cardax Inc, H2 2016 136

Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2016 137

Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 138

Parkinson's Disease - Pipeline by Cellceutix Corp, H2 2016 139

Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 140

Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2016 141

Parkinson's Disease - Pipeline by Clera Inc, H2 2016 142

Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2016 143

Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2016 144

Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145

Parkinson's Disease - Pipeline by Corium International Inc, H2 2016 146

Parkinson's Disease - Pipeline by Curemark LLC, H2 2016 147

Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 148

Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H2 2016 149

Parkinson's Disease - Pipeline by Depomed Inc, H2 2016 150

Parkinson's Disease - Pipeline by DermaXon LLC, H2 2016 151

Parkinson's Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 152

Parkinson's Disease - Pipeline by Dizlin Medical Design AB, H2 2016 153

Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2016 154

Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H2 2016 155

Parkinson's Disease - Pipeline by Eli Lilly and Company, H2 2016 156

Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2016 157

Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 158

Parkinson's Disease - Pipeline by FPRT Bio Inc, H2 2016 159

Parkinson's Disease - Pipeline by Genecode AS, H2 2016 160

Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H2 2016 161

Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 162

Parkinson's Disease - Pipeline by GenKyoTex SA, H2 2016 163

Parkinson's Disease - Pipeline by Genmab A/S, H2 2016 164

Parkinson's Disease - Pipeline by Genosco Inc, H2 2016 165

Parkinson's Disease - Pipeline by Genzyme Corp, H2 2016 166

Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2016 167

Parkinson's Disease - Pipeline by Harbor Therapeutics Inc, H2 2016 168

Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2016 169

Parkinson's Disease - Pipeline by Herantis Pharma Plc, H2 2016 170

Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 171

Parkinson's Disease - Pipeline by Horizon Pharma Plc, H2 2016 172

Parkinson's Disease - Pipeline by Huons Co Ltd, H2 2016 173

Parkinson's Disease - Pipeline by ICB International Inc, H2 2016 174

Parkinson's Disease - Pipeline by Immungenetics AG, H2 2016 175

Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H2 2016 176

Parkinson's Disease - Pipeline by Intec Pharma ltd, H2 2016 177

Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 178

Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2016 179

Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2016 180

Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2016 181

Parkinson's Disease - Pipeline by Iproteos SL, H2 2016 182

Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 183

Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2016 184

Parkinson's Disease - Pipeline by Khondrion BV, H2 2016 185

Parkinson's Disease - Pipeline by KineMed Inc, H2 2016 186

Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 187

Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 188

Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2016 189

Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 190

Parkinson's Disease - Pipeline by Longevity Biotech Inc, H2 2016 191

Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H2 2016 192

Parkinson's Disease - Pipeline by Lysosomal Therapeutics Inc, H2 2016 193

Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2016 194

Parkinson's Disease - Pipeline by M's Science Corp, H2 2016 195

Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H2 2016 196

Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H2 2016 197

Parkinson's Disease - Pipeline by MedImmune LLC, H2 2016 198

Parkinson's Disease - Pipeline by MeiraGTx Ltd, H2 2016 199

Parkinson's Disease - Pipeline by Merck & Co Inc, H2 2016 200

Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2016 201

Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H2 2016 202

Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H2 2016 203

Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 204

Parkinson's Disease - Pipeline by MitoDys Therapeutics Ltd, H2 2016 205

Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H2 2016 206

Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H2 2016 207

Parkinson's Disease - Pipeline by Neuralstem Inc, H2 2016 208

Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 209

Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 210

Parkinson's Disease - Pipeline by NeuroDerm Ltd, H2 2016 211

Parkinson's Disease - Pipeline by NeuroNascent Inc, H2 2016 212

Parkinson's Disease - Pipeline by NeurOp Inc, H2 2016 213

Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H2 2016 214

Parkinson's Disease - Pipeline by New World Laboratories Inc, H2 2016 215

Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H2 2016 216

Parkinson's Disease - Pipeline by nLife Therapeutics SL, H2 2016 217

Parkinson's Disease - Pipeline by NLS Pharma Group, H2 2016 218

Parkinson's Disease - Pipeline by Novartis AG, H2 2016 219

Parkinson's Disease - Pipeline by Novo Nordisk A/S, H2 2016 220

Parkinson's Disease - Pipeline by NsGene A/S, H2 2016 221

Parkinson's Disease - Pipeline by Omeros Corp, H2 2016 222

Parkinson's Disease - Pipeline by Oncodesign SA, H2 2016 223

Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 224

Parkinson's Disease - Pipeline by OPKO Health Inc, H2 2016 225

Parkinson's Disease - Pipeline by Orion Oyj, H2 2016 226

Parkinson's Disease - Pipeline by Oryzon Genomics SA, H2 2016 227

Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H2 2016 228

Parkinson's Disease - Pipeline by ParkCell AB, H2 2016 229

Parkinson's Disease - Pipeline by Peptron Inc, H2 2016 230

Parkinson's Disease - Pipeline by Pfizer Inc, H2 2016 231

Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2016 232

Parkinson's Disease - Pipeline by PharmatrophiX Inc, H2 2016 233

Parkinson's Disease - Pipeline by Pharmaxis Ltd, H2 2016 234

Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H2 2016 235

Parkinson's Disease - Pipeline by Pharnext SA, H2 2016 236

Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H2 2016 237

Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H2 2016 238

Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H2 2016 239

Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2016 240

Parkinson's Disease - Pipeline by Primary Peptides Inc, H2 2016 241

Parkinson's Disease - Pipeline by Proclara Biosciences Inc, H2 2016 242

Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H2 2016 243

Parkinson's Disease - Pipeline by Promius Pharma LLC, H2 2016 244

Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2016 245

Parkinson's Disease - Pipeline by Prothena Corp Plc, H2 2016 246

Parkinson's Disease - Pipeline by QR Pharma Inc, H2 2016 247

Parkinson's Disease - Pipeline by reMYND NV, H2 2016 248

Parkinson's Disease - Pipeline by Retrotope Inc, H2 2016 249

Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H2 2016 250

Parkinson's Disease - Pipeline by Saje Pharma LLC, H2 2016 251

Parkinson's Disease - Pipeline by SanBio Inc, H2 2016 252

Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 253

Parkinson's Disease - Pipeline by Saniona AB, H2 2016 254

Parkinson's Disease - Pipeline by Sellas Inc, H2 2016 255

Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H2 2016 256

Parkinson's Disease - Pipeline by Shire Plc, H2 2016 257

Parkinson's Disease - Pipeline by Sigma-Tau SpA, H2 2016 258

Parkinson's Disease - Pipeline by SignPath Pharma Inc, H2 2016 259

Parkinson's Disease - Pipeline by Signum Biosciences Inc, H2 2016 260

Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 261

Parkinson's Disease - Pipeline by STATegics Inc, H2 2016 262

Parkinson's Disease - Pipeline by Stelic Institute & Co Inc, H2 2016 263

Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 264

Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 265

Parkinson's Disease - Pipeline by Synthonics Inc, H2 2016 266

Parkinson's Disease - Pipeline by Takara Bio Inc, H2 2016 267

Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 268

Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2016 269

Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2016 270

Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2016 271

Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 272

Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H2 2016 273

Parkinson's Disease - Pipeline by Trevena Inc, H2 2016 274

Parkinson's Disease - Pipeline by TyrNovo Ltd, H2 2016 275

Parkinson's Disease - Pipeline by UniQure NV, H2 2016 276

Parkinson's Disease - Pipeline by Vanton Research Laboratory LLC, H2 2016 277

Parkinson's Disease - Pipeline by Varinel Inc, H2 2016 278

Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 279

Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280

Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 281

Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H2 2016 282

Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 283

Assessment by Monotherapy Products, H2 2016 284

Assessment by Combination Products, H2 2016 285

Number of Products by Stage and Target, H2 2016 287

Number of Products by Stage and Mechanism of Action, H2 2016 298

Number of Products by Stage and Route of Administration, H2 2016 310

Number of Products by Stage and Molecule Type, H2 2016 312

Parkinson's Disease - Dormant Projects, H2 2016 836

Parkinson's Disease - Dormant Projects (Contd..1), H2 2016 837

Parkinson's Disease - Dormant Projects (Contd..2), H2 2016 838

Parkinson's Disease - Dormant Projects (Contd..3), H2 2016 839

Parkinson's Disease - Dormant Projects (Contd..4), H2 2016 840

Parkinson's Disease - Dormant Projects (Contd..5), H2 2016 841

Parkinson's Disease - Dormant Projects (Contd..6), H2 2016 842

Parkinson's Disease - Dormant Projects (Contd..7), H2 2016 843

Parkinson's Disease - Dormant Projects (Contd..8), H2 2016 844

Parkinson's Disease - Dormant Projects (Contd..9), H2 2016 845

Parkinson's Disease - Dormant Projects (Contd..10), H2 2016 846

Parkinson's Disease - Dormant Projects (Contd..11), H2 2016 847

Parkinson's Disease - Dormant Projects (Contd..12), H2 2016 848

Parkinson's Disease - Dormant Projects (Contd..13), H2 2016 849

Parkinson's Disease - Dormant Projects (Contd..14), H2 2016 850

Parkinson's Disease - Dormant Projects (Contd..15), H2 2016 851

Parkinson's Disease - Dormant Projects (Contd..16), H2 2016 852

Parkinson's Disease - Dormant Projects (Contd..17), H2 2016 853

Parkinson's Disease - Dormant Projects (Contd..18), H2 2016 854

Parkinson's Disease - Dormant Projects (Contd..19), H2 2016 855

Parkinson's Disease - Dormant Projects (Contd..20), H2 2016 856

Parkinson's Disease - Dormant Projects (Contd..21), H2 2016 857

Parkinson's Disease - Dormant Projects (Contd..22), H2 2016 858

Parkinson's Disease - Dormant Projects (Contd..23), H2 2016 859

Parkinson's Disease - Dormant Projects (Contd..24), H2 2016 860

Parkinson's Disease - Discontinued Products, H2 2016 861

Parkinson's Disease - Discontinued Products (Contd..1), H2 2016 862

Parkinson's Disease - Discontinued Products (Contd..2), H2 2016 863

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

2-BBB Medicines BV, 4P Therapeutics LLC, AbbVie Inc, AC Immune SA, Acelot Inc, Acorda Therapeutics Inc, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Aeolus Pharmaceuticals Inc, AFFiRiS AG, Amabiotics SAS, Amarantus Bioscience Holdings Inc, American Gene Technologies International Inc, Anavex Life Sciences Corp, Angita BV, Antoxis Ltd, Aoxing Pharmaceutical Company Inc, APeT Holding BV, ApoPharma Inc, Aposense Ltd, Araclon Biotech SL, ArmaGen Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc, AudioCure Pharma GmbH, Berg LLC, Bial - Portela & Ca SA, Bio-Modeling Systems SAS, BioArtic AB, Biogen Inc, BioHealthonomics Inc, Biopharm GmbH, Biotie Therapies Corp, BrainStorm Cell Therapeutics Inc, Calico LLC, Cantabio Pharmaceuticals Inc, Cardax Inc, Carna Biosciences Inc, Cell Cure Neurosciences Ltd, Cellceutix Corp, CHA Bio & Diostech Co Ltd, Chipscreen Biosciences Ltd, Clera Inc, Clevexel Pharma SA, Contera Pharma ApS, ContraVir Pharmaceuticals Inc, Corium International Inc, Curemark LLC, Daewoong Pharmaceutical Co Ltd, Denali Therapeutics Inc, Depomed Inc, DermaXon LLC, Diffusion Pharmaceuticals Inc, Dizlin Medical Design AB, Domain Therapeutics SA, Edison Pharmaceuticals Inc, Eli Lilly and Company, Ensemble Therapeutics Corp, Fabre-Kramer Pharmaceuticals Inc, FPRT Bio Inc, Genecode AS, Generon (Shanghai) Corp Ltd, Genervon Biopharmaceuticals LLC, GenKyoTex SA, Genmab A/S, Genosco Inc, Genzyme Corp, H. Lundbeck A/S, Harbor Therapeutics Inc, Heptares Therapeutics Ltd, Herantis Pharma Plc, Hisamitsu Pharmaceutical Co Inc, Horizon Pharma Plc, Huons Co Ltd, ICB International Inc, Immungenetics AG, Impel NeuroPharma Inc, Intec Pharma ltd, Integrative Research Laboratories Sweden AB, InterMed Discovery GmbH, International Stem Cell Corp, Io Therapeutics Inc, Iproteos SL, Jeil Pharmaceutical Co Ltd, Kainos Medicine Inc, Khondrion BV, KineMed Inc, Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Living Cell Technologies Ltd, Longevity Biotech Inc, Luye Pharma Group Ltd, Lysosomal Therapeutics Inc, M et P Pharma AG, M's Science Corp, M3 Biotechnology Inc, MedGenesis Therapeutix Inc, MedImmune LLC, MeiraGTx Ltd, Merck & Co Inc, Metabolic Solutions Development Company LLC, Minerva Neurosciences Inc, Mission Therapeutics Ltd, Mitochon Pharmaceuticals Inc, MitoDys Therapeutics Ltd, Motac Neuroscience Ltd, Netherlands Translational Research Center BV, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neuren Pharmaceuticals Ltd, NeuroDerm Ltd, NeuroNascent Inc, NeurOp Inc, Neuropore Therapies Inc, New World Laboratories Inc, Newron Pharmaceuticals SpA, nLife Therapeutics SL, NLS Pharma Group, Novartis AG, Novo Nordisk A/S, NsGene A/S, Omeros Corp, Oncodesign SA, Ono Pharmaceutical Co Ltd, OPKO Health Inc, Orion Oyj, Oryzon Genomics SA, Oxford BioMedica Plc, ParkCell AB, Peptron Inc, Pfizer Inc, Pharma Two B Ltd, PharmatrophiX Inc, Pharmaxis Ltd, Pharmicell Co Ltd, Pharnext SA, Phenomenome Discoveries Inc, Plex Pharmaceuticals Inc, Prana Biotechnology Ltd, Prexton Therapeutics SA, Primary Peptides Inc, Proclara Biosciences Inc, Promentis Pharmaceuticals Inc, Promius Pharma LLC, Proteostasis Therapeutics Inc, Prothena Corp Plc, QR Pharma Inc, reMYND NV, Retrotope Inc, Sage Therapeutics Inc, Saje Pharma LLC, SanBio Inc, Saneron CCEL Therapeutics Inc, Saniona AB, Sellas Inc, Serina Therapeutics Inc, Shire Plc, Sigma-Tau SpA, SignPath Pharma Inc, Signum Biosciences Inc, SK Biopharmaceuticals Co Ltd, STATegics Inc, Stelic Institute & Co Inc, Sun Pharma Advanced Research Company Ltd, Sunovion Pharmaceuticals Inc, Synthonics Inc, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, TauRx Therapeutics Ltd, TechnoPhage SA, Teikoku Pharma USA Inc, Teva Pharmaceutical Industries Ltd, Titan Pharmaceuticals Inc, Trevena Inc, TyrNovo Ltd, UniQure NV, Vanton Research Laboratory LLC, Varinel Inc, VistaGen Therapeutics Inc, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, vTv Therapeutics Inc, Wellstat Therapeutics Corp

select a license

Single User License
USD 2500 INR 165525
Site License
USD 5000 INR 331050
Corporate User License
USD 7500 INR 496575

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com